Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease.

Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease.
复制标题

DOI：
10.1097/00019442-200201000-00004
复制
发表时间：
2002
期刊：
The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry
影响因子：
--
通讯作者：
K. Shoghi-Jadid;G. Small;Eric Agdeppa;V. Kepe;L. Ercoli;P. Siddarth;S. Read;N. Satyamurthy;A. Petrič;Sung-Cheng Huang;J. Barrio
K. Shoghi-Jadid;G. Small;Eric Agdeppa;V. Kepe;L. Ercoli;P. Siddarth;S. Read;N. Satyamurthy;A. Petrič;Sung-Cheng Huang;J. Barrio
中科院分区：
其他
文献类型：
--
作者：
K. Shoghi-Jadid;G. Small;Eric Agdeppa;V. Kepe;L. Ercoli;P. Siddarth;S. Read;N. Satyamurthy;A. Petrič;Sung-Cheng Huang;J. Barrio

文献摘要

被引文献

相似文献

作者使用2-（1-（6-[（2-[18F]氟乙基）（甲基）氨基]-2-萘基）亚乙基）丙二腈（[18F]FDDNP），一种2-（1-[6-（二甲基氨基）-2-萘基]亚乙基）丙二腈（DDNP），结合正电子发射断层扫描，以确定神经元缠结（NFT）和β-淀粉样老年斑（AP）的定位和负荷阿尔茨海默病（AD）患者的大脑中。先前的工作说明了[18 F]FDDNP与合成β-淀粉样蛋白（1-40）原纤维以及与人类AD脑标本中的NFT和AP的体外结合特征。在本研究中，在AP和NFT密集的脑区观察到更大的积累和更慢的清除，并与较低的记忆表现评分相关。AD患者（n=9）中受AD影响的脑区中探针的相对停留时间显著大于对照受试者（n=7; p=0.0007）。这种用于监测AP和NFT发展的非侵入性技术有望促进AD患者的诊断评估，并有助于实验治疗期间的反应监测。
The authors used 2-(1-(6-[(2-[18F]fluoroethyl)(methyl)amino]-2-naphthyl)ethylidene)malononitrile ([18F]FDDNP), a hydrophobic radiofluorinated derivative of 2-(1-[6-(dimethylamino)-2-naphthyl]ethylidene)malononitrile (DDNP), in conjunction with positron emission tomography to determine the localization and load of neurofibrillary tangles (NFTs) and beta-amyloid senile plaques (APs) in the brains of living Alzheimer disease (AD) patients. Previous work illustrated the in vitro binding characteristics of [18F]FDDNP to synthetic beta-amyloid(1-40) fibrils and to NFTs and APs in human AD brain specimens. In the present study, greater accumulation and slower clearance was observed in AP- and NFT-dense brain areas and correlated with lower memory performance scores. The relative residence time of the probe in brain regions affected by AD was significantly greater in patients with AD (n=9) than in control subjects (n=7; p=0.0007). This noninvasive technique for monitoring AP and NFT development is expected to facilitate diagnostic assessment of patients with AD and assist in response-monitoring during experimental treatments.